Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Chimerix, Inc. stock logo
CMRX
Chimerix
$8.54
$8.54
$0.75
$8.55
$801.09M-0.172.76 million shsN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$1.71
+0.6%
$1.81
$1.32
$2.72
$248.27M1.71192,014 shs16,498 shs
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$0.25
+0.9%
$0.27
$0.17
$0.48
$358.91M-1.122.15 million shs1.33 million shs
Savara Inc. stock logo
SVRA
Savara
$2.14
+1.7%
$2.60
$1.89
$5.11
$362.96M0.311.27 million shs1.11 million shs
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
$1.30
$1.30
$0.25
$1.40
$70.12M1.32515,333 shsN/A
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Chimerix, Inc. stock logo
CMRX
Chimerix
0.00%0.00%0.00%+0.12%+890.14%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
+3.03%+8.28%-8.60%+5.59%-9.57%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
+3.49%-2.42%-9.14%+17.33%-40.63%
Savara Inc. stock logo
SVRA
Savara
+2.44%-4.11%-12.50%-27.59%-51.16%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Chimerix, Inc. stock logo
CMRX
Chimerix
0.7511 of 5 stars
1.00.00.04.10.61.70.6
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
0.9151 of 5 stars
3.51.00.00.00.00.00.0
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.0097 of 5 stars
0.01.00.00.00.00.00.0
Savara Inc. stock logo
SVRA
Savara
1.828 of 5 stars
3.31.00.00.00.03.30.6
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Chimerix, Inc. stock logo
CMRX
Chimerix
2.00
Hold$8.53-0.08% Downside
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.00
Buy$7.00309.36% Upside
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.00
N/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
2.60
Moderate Buy$5.60162.30% Upside
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CMRX, NWBO, IMMP, SVRA, and ZYNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/29/2025
Savara Inc. stock logo
SVRA
Savara
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$6.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetIn-Line ➝ In-Line$3.00 ➝ $2.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $8.00
5/28/2025
Savara Inc. stock logo
SVRA
Savara
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$8.00 ➝ $7.00
(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Chimerix, Inc. stock logo
CMRX
Chimerix
$212K3,778.71N/AN/A$2.17 per share3.94
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
$5.14M48.59N/AN/A$1.05 per share1.63
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
$1.38M262.30N/AN/A($0.07) per share-3.55
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/A$1.00 per shareN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/A$1.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Chimerix, Inc. stock logo
CMRX
Chimerix
-$82.10M-$0.99N/AN/AN/AN/A-50.78%-44.94%8/11/2025 (Estimated)
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
-$28.01MN/A0.00N/AN/AN/AN/AN/A7/29/2025 (Estimated)
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
-$83.78M-$0.07N/AN/A-5,757.57%N/A-303.49%8/7/2025 (Estimated)
Savara Inc. stock logo
SVRA
Savara
-$95.88M-$0.48N/AN/AN/AN/A-65.88%-52.35%8/11/2025 (Estimated)
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/A

Latest CMRX, NWBO, IMMP, SVRA, and ZYNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A-$0.01N/A-$0.01N/A$0.38 million
5/13/2025Q1 2025
Savara Inc. stock logo
SVRA
Savara
-$0.12-$0.12N/A-$0.12N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Chimerix, Inc. stock logo
CMRX
Chimerix
N/AN/AN/AN/AN/A
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/AN/AN/AN/AN/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/AN/AN/AN/AN/A
Savara Inc. stock logo
SVRA
Savara
N/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Chimerix, Inc. stock logo
CMRX
Chimerix
N/A
6.33
6.33
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
N/A
18.86
N/A
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
N/A
0.06
0.06
Savara Inc. stock logo
SVRA
Savara
0.20
14.91
14.91
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/A
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
45.42%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2.32%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
0.04%
Savara Inc. stock logo
SVRA
Savara
87.93%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
11.23%

Insider Ownership

CompanyInsider Ownership
Chimerix, Inc. stock logo
CMRX
Chimerix
13.10%
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
3.07%
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
8.70%
Savara Inc. stock logo
SVRA
Savara
5.33%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
13.04%
CompanyEmployeesShares OutstandingFree FloatOptionable
Chimerix, Inc. stock logo
CMRX
Chimerix
9093.80 million78.15 millionOptionable
Prima BioMed Ltd stock logo
IMMP
Prima BioMed
2,021146.04 million141.56 millionOptionable
Northwest Biotherapeutics, Inc. stock logo
NWBO
Northwest Biotherapeutics
201.46 billion1.33 billionNot Optionable
Savara Inc. stock logo
SVRA
Savara
N/A172.84 million163.63 millionOptionable
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2553.94 million46.91 millionOptionable

Recent News About These Companies

Harmony Biosciences: If It Ain't Broke
US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
GW Pharma's cannabis-derived epilepsy drug approved in EU
20 Countries With Highest Rate of Epilepsy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Chimerix stock logo

Chimerix NASDAQ:CMRX

$8.54 0.00 (0.00%)
As of 04/21/2025

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Prima BioMed stock logo

Prima BioMed NASDAQ:IMMP

$1.71 +0.01 (+0.59%)
As of 03:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.

Northwest Biotherapeutics stock logo

Northwest Biotherapeutics OTCMKTS:NWBO

$0.25 +0.00 (+0.85%)
As of 12:59 PM Eastern

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Savara stock logo

Savara NASDAQ:SVRA

$2.13 +0.04 (+1.67%)
Closing price 03:58 PM Eastern
Extended Trading
$2.19 +0.06 (+2.81%)
As of 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Zynerba Pharmaceuticals stock logo

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.